Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Many ovarian cancer patients have been offered different standard cytostatics and gradually
develop chemo-resistance. However, a considerable fraction of these patients are still in
good general health and have a strong wish for further treatment.
Cabazitaxel (Jevtana®) is a new taxane with effect in breast and prostatic cancer. In both
tumors it has shown effect in patients refractory to docetaxel. Therefore, it could be
anticipated that cabazitaxel may also have an effect in chemo-resistant ovarian cancer.
The aim of the study is to investigate whether cabazitaxel could be a reasonable treatment
option in patients with chemo-resistant and refractory ovarian cancer with regard to effect
and toxicity.